Novel Ruthenium - Gamma-linolenic Acid Complex Inhibits C6 Rat Glioma Cell Proliferation In Vitro and in the Orthotopic C6 Model In Vivo After Osmotic Pump Infusion

Author(s)

Miyake, Juliano Andreoli ; Benadiba, Marcel ; Ribeiro, Geise ; Silva, Denise De Oliveira ; Colquhoun, Alison

• Document type: Journal article
• Source: ANTICANCER RESEARCH; v. 34, n. 4, p. 11-pg., 2014-04-01.

Abstract

Aim: Gliomas are primary brain tumours. Gamma-linolenic acid (GLA) exerts anti-proliferative effects. Several ruthenium-containing complexes have antiproliferative effects and can be used as adjuvant therapies in cisplatin-resistant cancer. The present study reports on the anti-proliferative properties and effects on tumour morphology of a novel diruthenium-GLA complex (Ru(2)GLA) and its comparison with GLA in the C6 rat glioma model both in vitro and in vivo. Materials and Methods: In vitro and in vivo experiments were performed on C6 glioma rat cells, and in an orthotopic model. Results: Ru(2)GLA (100 mu M) appears to be an inhibitor of C6 rat glioma cell proliferation. The nuclear area of Ru(2)GLA-treated cells was 2.18-times larger than that of control cells, suggesting DNA replication occurred but mitosis was blocked in the G(2)-M phase. Ru(2)GLA (2 mM) inhibited C6 cell proliferation in vivo and the changes in tumor morphology confirm both cellular uptake and collagen fibre-binding in the extracellular matrix. Conclusion: Ru(2)GLA appears to be a low-toxicity drug and a potential candidate for anti-proliferative therapy of glioma. (AU)

• FAPESP's process: 05/60596-8 - Complex species with potential for application in bio-organics, catalysis, pharmacology and environmental chemistry: conception, preparation, characterization and reactivity
• Grantee: Ana Maria da Costa Ferreira
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 11/06592-1 - Anti-inflammatory and antitumor metallotherapeutic drugs: reactivity, properties and interactions with biocompatible hosts
• Grantee: Denise de Oliveira Silva
• Support Opportunities: Regular Research Grants